Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Carline J van den DriesRomin PajouheshniaHendrika A van den HamPatrick C SouvereinKarel G M MoonsArno W HoesGeert-Jan GeersingSander van Doorn

Published in: British journal of clinical pharmacology (2022)

In this large population-based study, the hazards for ischaemic stroke and major bleeding were low, and similar in AF patients receiving an off-label reduced NOAC dose compared with on-label standard dose users, while non-major bleeding risk appeared to be lower and mortality risk higher. Caution towards prescribing an off-label reduced NOAC dose is therefore required.

Keyphrases

oral anticoagulants
atrial fibrillation
primary care
emergency department